Voyager Therapeutics (VYGR) investor relations material

Executive summary

• Focused on developing genetic medicines for neurological diseases, with a pipeline including Alzheimer's, Friedreich's ataxia, Parkinson's, ALS, and other CNS disorders.

• Proprietary TRACER AAV capsid and NeuroShuttle non-viral delivery platforms underpin both wholly-owned and partnered programs.

• Completed IND-enabling GLP toxicology for VY1706 and NBIB-223, with clinical entry expected in H2 2026.

• Key collaborations with Neurocrine, Novartis, Alexion, and Transition Bio provide significant non-dilutive funding and future milestone potential.

• Multiple presentations at ASGCT 2026, including late-breaking data on VY1706.

Financial highlights

• Collaboration revenue was $2.6M for Q1 2026, down from $6.5M in Q1 2025, reflecting lower milestone and reimbursement activity.

• Net loss for Q1 2026 was $27.9M, an improvement from $31.0M in Q1 2025, driven by reduced R&D and G&A expenses.

• Cash, cash equivalents, and marketable securities totaled $171.7M as of March 31, 2026.

• Operating expenses decreased to $32.9M from $41.2M year-over-year, mainly due to portfolio prioritization and cost-cutting.

• R&D expenses decreased to $24.6M from $31.5M year-over-year, and G&A expenses fell to $8.3M from $9.6M.

Outlook and guidance

• Existing cash and expected collaboration reimbursements are projected to fund operations into 2028.

• Planned initiation of a Phase 1 clinical trial for VY1706 in Alzheimer's in the second half of 2026, pending IND clearance.

• Initial efficacy data from the VY7523 Phase 1 MAD trial in Alzheimer's expected in the second half of 2026.

• Neurocrine plans to initiate a clinical trial with NBIB-223 for Friedreich's ataxia in H2 2026, pending FDA IND clearance.